New shot for high blood pressure takes first step in human testing

NCT ID NCT07529600

Completed Disease control Sponsor: Arnatar Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a single injection of ART101 in 40 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo. The goal is to gather initial safety data before testing in people with high blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ART101 injection
What this could lead to: If successful, this could lead to a new injectable treatment option for high blood pressure.
What could go wrong: This is a very early Phase 1 trial in only 40 healthy people, so it is not yet tested in patients with hypertension. The drug may prove unsafe or ineffective in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION (HTN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION (HTN)

Contacts and locations

Show contact details

Locations

Beijing Friendship Hospital, Capital Medical University

Beijing, China
Suzhou Arnatar Therapeutics Co., Ltd

Suzhou, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.